Alimera Completes Recruitment for its Landmark NEW DAY Study
24 mai 2023 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, May 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
18 mai 2023 07h00 HE
|
Alimera Sciences, Inc.
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...
Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
17 mai 2023 16h05 HE
|
Alimera Sciences, Inc.
ATLANTA, May 17, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports First Quarter 2023 Results
15 mai 2023 07h50 HE
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022Global End User Demand Up 14% vs. First Quarter of 2022 Financial Results and Corporate Update Conference Call Cancelled ...
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
08 mai 2023 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress
20 avr. 2023 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
03 avr. 2023 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, April 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Announces 2022 Financial Results and Business Update
31 mars 2023 08h00 HE
|
Alimera Sciences, Inc.
• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term...
Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
27 mars 2023 08h00 HE
|
Alimera Sciences, Inc.
Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000Completes $12 million private placement of preferred stock and warrants with conversion...
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
24 mars 2023 16h05 HE
|
Alimera Sciences, Inc.
ATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...